Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor for COPD

Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor ...
Seeking Alpha

Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*

-Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of ...

Merck completes major acquisition of British biopharma company

RAHWAY, N.J.- Merck has completed its $10 billion buyout of the British biopharmaceutical company Verona. The deal was first ...

Verona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD Portfolio

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Verona Pharma plc is one of them.
Verywell Health on MSN

Don’t Combine These COPD Medicines

Check this table to make sure you can use your COPD inhalers together Medically reviewed by Sanja Jelic, MD Most people with chronic obstructive pulmonary disease (COPD) use an inhaler every day to ...

Inhalers drive carbon emissions equivalent to 530,000 cars each year, study shows

Inhalers are the frontline treatment for asthma and COPD, but they come with a steep environmental cost, according to a new ...
Seeking Alpha

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive ...

Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases Through this acquisition Merck will add ...